T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1279)	7/24/2002 2:04:48 AM
From: scaram(o)uche	Read Replies (2) of 2243

Wednesday July 24, 2:00 am Eastern Time Press Release SOURCE: Oxford GlycoSciences Plc OGS Announces Decision by Ethics Committee in Israel to End Temporary Suspension of Vevesca (OGT 918) Trials OXFORD, UK, July 24 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (LSE: OGS, Nasdaq: OGSI) has been informed that the Ethics Committee at the Shaare Zedek Medical Centre in Israel, that recommended Vevesca (OGT 918) administration be temporarily stopped in April 2002, has removed its suspension of Vevesca (OGT 918) trials after reviewing additional clinical data. Following the initial April 2002 decision at this hospital, Independent Review Boards of all other clinical study sites assessed the situation and allowed treatment at such sites to continue without interruption. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next